Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495647 | 1.00 | CNR2 (0.53) | CNR2CNR1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL3494259 | 0.93 | SMN1; SMN2 (0.51) | CNR2CNR1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL17532425 | 0.91 | RAB9A (0.52) | CNR2CNR1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL13311367 | 0.86 | L3MBTL1 (0.42) | CNR2CNR1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL3495026 | 0.86 | L3MBTL1 (0.42) | CNR2CNR1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL17532421 | 0.86 | ALDH1A1 (0.46) | CNR2SMN1; SMN2MEN1RAB9AKMT2A | |
| SCHEMBL13311489 | 0.86 | ALDH1A1 (0.46) | CNR2SMN1; SMN2MEN1RAB9AKMT2A | |
| SCHEMBL25474242 | 0.84 | CNR2 (0.39) | CNR2CNR1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL17532429 | 0.82 | PPM1B (0.48) | SMN1; SMN2MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL13311411 | 0.80 | PPM1B (0.52) | SMN1; SMN2MEN1RAB9AKMT2APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | claimed |
| EP-2086534-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | Genetic Technologies Limited (AU) | 2009-08-12 | — | — | EP | claimed |
| WO-2008058342-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2008-05-22 | — | — | WO | claimed |
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | PPP1R10, TASP1, PPP5C | CNR2 4377/4885CNR1 3767/4885SMN1; SMN2 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.